|July 8, 2014|
|09:15 EDT||ANR, WLT, NURO, ABBV, IPCI, CGI, TFM, SHPG, MIC, TXMD, GRPN||On The Fly: Pre-market Movers|
HIGHER: Shire (SHPG), up 1% after AbbVie (ABBV) raises buyout offer for fourth time, to GBP 22.44 in cash and 0.8568 AbbVie shares per Shire share. AbbVie shares down about 1% in pre-market trading following the news... Groupon (GRPN), up 5.7% after upgraded at B. Riley... TherapeuticsMD (TXMD), up 21.8% after FBR Capital initiated the stock with an Outperform rating and $34 price target... NeuroMetrix (NURO), up 45% after wearable technology for treatment of chronic pain cleared by FDA... Celadon Group (CGI), up 7% after upgraded at Stifel... Macquarie Infrastructure (MIC), up 6.3% after acquiring remainder of IMTT for $1.025B in cash, stock. LOWER: Intellipharmaceutics (IPCI), down 10% after Q2 earnings lower than expected... The Fresh Market (TFM), down 6.6% after downgraded at Goldman... Walter Energy (WLT), down 4%, Alpha Natural (ANR), down 1%, after coal sector estimates lowered at Morgan Stanley.
News For SHPG;ABBV;GRPN;TFM;NURO;TXMD;CGI;WLT;MIC;IPCI;ANR From The Last 14 Days
|September 23, 2015|
|07:54 EDT||GRPN||Groupon restructuring a sign of maturation, says Brean Capital|
Subscribe for More Information
|September 22, 2015|
|20:02 EDT||ABBV||Clinton vows $250 cap on monthly drug costs in blast against biotechs, insurers|
Democratic presidential candidate Hillary Clinton railed against biotech companies as well as health insurers at a community health care forum in Iowa on Tuesday. Clinton began her speech by praising the Affordable Care Act, but quickly noted that she wants to strengthen it due to what she called the rising cost of prescription drugs. She explained, "Our pharmaceutical and biotechnology industries deserve credit... [But] too often, these drugs cost a fortune. Now, sometimes there is a good reason for that. Scientific breakthroughs are often the result of major investment... so it may makes sense, for a short period of time, to have to charge a lot of money for a drug. But when a drug has no competition, when there aren't any other treatments that can do what it does, pharmaceutical companies can charge astronomical fees far beyond anything that it would take to recoup their investment, and far beyond what they charge consumers anywhere else in the world outside of America." Referencing the recent criticism against Turing Pharmaceuticals, Clinton went on to say that "pharmaceutical companies that acquire an existing affordable drug that people rely on, and then turn around and charge a fortune for it, [are just betting] on the fact that desperate people will find some way to pay for it." Preemptively responding to questions of whether greater regulation will dampen investment, Clinton commented that "some people worry that my proposals will threaten innovation, but I have designed a plan that will do exactly the opposite... Under my plan, drug companies that want to keep getting federal support will have to redirect more of their profits into meaningful investments in research and development." Clinton also criticized incremental drug improvements, saying that "too often, so-called new drugs are really old drugs that have just been tweaked a little bit, but then they're marketed as breakthrough drugs and they're sold for high prices." The Democratic candidate went on to condemn advertising in the drug industry, remarking that "I also want to tackle direct to consumer advertising... Other countries ban these ads because they are so often misleading. But at the very least, we shouldn't be encouraging them with corporate write-offs... Under my plan, we will instead use that taxpayer money to fund innovation... I would also like to make sure any ads the drug industry does run are approved by the FDA." Moving more broadly onto Medicaid and health insurers, Clinton stated, "I believe Medicare should be able to negotiate for lower prices for its members... I will require drug companies to provide higher rebates for prescription drugs to low income Medicare patients, just like they have to do for Medicaid patients... I think the insurance companies need to be put on notice." Providing more concrete details of her plan, Clinton concluded, "I will cap out of pocket drug costs for working families. You won't have to pay more than $250 a month for covered medications... Particularly for people who have a chronic illness. Also under my plan, you will be able to import cheaper drugs from other countries legally. If the medicine you need costs less in Canada, you should be able to buy it from Canada or any other country that meets our safety standards... I will also make sure we have more generics on the market [by boosting funding for] the FDA's office of generic drugs."
|17:35 EDT||ABBV||Hillary Clinton vows to cap out-of-pocket drug costs at $250 per month|
Presidential candidate Hillary Clinton said in a tweet that, "Under my plan, I'll cap out-of-pocket drug costs for families. You won't have to pay more than $250/month for covered medications." Reference Link
|16:36 EDT||GRPN||On The Fly: Top stock stories for Tuesday|
Stocks on Wall Street began the session sharply lower and remained that way throughout the session. There was little in the way of buying as each of the major equity indexes slid over 1% and the market internals were decidedly negative. The auto industry and biotech sector were both notably weak, after the French government called for an investigation into the entire auto industry in the wake of the Volkswagen (VLKAY) emissions scandal and Democratic Presidential hopeful Hillary Clinton presented a plan to limit the cost of drugs for consumers. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.6% to 224.5 in July, which was better than the 0.4% rise that was expected. The Richmond Fed factory index fell to -5 in September, versus the reading of 2 that was expected. In Asia, the Asian Development Bank cut its growth forecast for the region, citing a weaker outlook for China and India and a delayed recovery in the world's advanced economies. The bank now sees the Chinese economy growing 6.8% this year and 6.7% next year, down from its previous forecasts of 7.2% and 7%, respectively. COMPANY NEWS: Lloyd Blankfein, Goldman Sachs (GS) Chairman and CEO, disclosed that he was diagnosed with lymphoma. "Fortunately, my form of lymphoma is highly curable and my doctors' and my own expectation is that I will be cured," Blankfein stated in an open letter that was shared by the bank... Bank of America (BAC) shareholders approved a proposal to ratify the 2014 amendments to the company's bylaws that permitted the board of directors to determine its leadership structure, meaning Brian Moynihan can retain his dual role as both Chairman and CEO... Shares of several fertilizer companies slid after Mosaic (MOS) announced it will reduce its potash production in response to current crop nutrient market conditions, primarily related to delayed fertilizer purchases in Brazil and North America. Shares of Mosaic finished the day down 7% at $33.87 following last night's announcement, while Potash (POT) fell 6.5% and Agrium (AGU) dropped 3.5%. MAJOR MOVERS: Among the notable gainers was Ashland (ASH), which advanced $2.78, or 2.6%, to $108.50 after announcing it will proceed with a plan to separate into two independent, publicly traded companies. Also higher was Weatherford (WFT), which gained 90c, or 10.7%, to $9.31 after cancelling plans for a public share offering, after which research firms Jefferies and Iberia both reiterated Buy-equivalent ratings on the stock. Among the noteworthy losers were Office Depot (ODP) and Staples (SPLS), which declined a respective 4% and 5.8% after the New York Post quoted a source as saying the FTC may move to block their merger plan. Also lower was Groupon (GRPN), which slipped 2.2% to $4.08 after announcing plans to cut 1,100 jobs related primarily to its international operations. ConAgra (CAG), Carnival (CCL), and CarMax (KMX) fell 7%, 5.5%, and 4.65%, respectively, following their quarterly earnings reports. INDEXES: The Dow fell 179.72, or 1.09%, to 16,330.47, the Nasdaq lost 72.23, or 1.5%, to 4,756.72, and the S&P 500 dropped 24.23, or 1.23%, to 1,942.74.
|12:14 EDT||GRPN||On The Fly: Top stock stories at midday|
Stocks began the session deep in negative territory and have remained there throughout the morning. There has been little in the way of buying as the downward pressure in the market has not shown any sign of letting up. There is also little in the way of explanation as to why the market is so weak other than continued disappointment in the Fed's interest rate decision and the ongoing concern over China's economic growth. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.6% to 224.5 in July, which was better than the 0.4% rise that was expected. The Richmond Fed factory index fell to -5 in September, versus the reading of 2 that was expected. COMPANY NEWS: Shares of Groupon (GRPN) slumped 2.5% after the online and mobile deal provider said it plans to cut more than 1,000 jobs relating primarily to the company's international operations. The news is the latest in a recent run of job cut announcements, after HP Enterprise said last week that it expects 25,000-30,000 people to leave the company and Johnson Controls (JCI) recently announced plans to reduce its global salaried workforce by as many as 3,000 people... Lloyd Blankfein, Goldman Sachs (GS) chairman and CEO, disclosed that he was told by doctors that he has lymphoma. "Fortunately, my form of lymphoma is highly curable and my doctors' and my own expectation is that I will be cured," Blankfein stated in an open letter that was shared by the bank. MAJOR MOVERS: Among the notable gainers was Weatherford (WFT), which rose 9.6% after stating that it has decided not to pursue its previously announced concurrent public offerings of ordinary shares of the company and mandatorily exchangeable subordinated notes. Also higher was Vascular Biogenics (VBLT), which gained 15% to around $9.30 per share after the stock was initiated with a Buy rating and $25 price target at Chardan. Among the noteworthy losers following their earnings reports were ConAgra (CAG) and Carnival (CCL), which each fell more than 5%, and Red Hat (RHT), which slid 2%. Also lower were shares of Staples (SPLS) and Office Depot (ODP), which fell 7% and 8%, respectively, after the New York Post said a top FTC regulator may be leaning toward recommending against approving their merger agreement. INDEXES: Near midday, the Dow was down 263.77, or 1.6%, to 16,246.42, the Nasdaq was down 99.52, or 2.06%, to 4,729.44, and the S&P 500 was down 32.51, or 1.65%, to 1,934.46.
|11:06 EDT||GRPN||Groupon slumps after announcing plans to cut jobs, exit markets|
Shares of Groupon (GRPN) are slumping in morning trading after the company said it plans to cut more than 1,000 jobs relating primarily to the company's international operations. WHAT'S NEW: Groupon said this morning in a regulatory filing that its board approved a restructuring program under which it will cut 1,100 jobs and take a pre-tax charge of $35M. Of the pre-tax charges, Groupon said it will record $22M-$24M in the third quarter of 2015. The restructuring actions are expected to be complete by September 2016, the company said, adding that "substantially all of the pre-tax charges are expected to be paid in cash and will relate to employee severance and compensation benefits." Cost savings from the cuts will be reinvested in the business, Groupon said. WHAT'S NOTABLE: As part of the restructuring, Groupon will cease operations in several international markets: Morocco, Taiwan, Thailand, Panama, The Philippines, Puerto Rico and Uruguay. The closures come on top of recent exits in Turkey and Greece, as well as a sale of part of its stake in Groupon India to Sequoia. Rich Williams, the company's chief operating officer and president of North America, commented in a blog post that the 1,100 jobs that will be eliminated "over the next several months" will mostly come from the Deal Factory and Customer Service units. "We believe that in order for our geographic footprint to be an even bigger advantage, we need to focus our energy and dollars on fewer countries," Williams explained, adding that "just as our business has evolved from a largely hand-managed daily deal site to a true ecommerce technology platform, our operational model has to evolve." Williams also said that "in order for our geographic footprint to be an even bigger advantage, we need to focus our energy and dollars on fewer countries," and the countries it is exiting are "where the required investment and market potential don't align." PRICE ACTION: Groupon is down 1.7% to $4.10 in morning trading. Shares are down over 50% year-to-date.
|09:20 EDT||GRPN||On The Fly: Pre-market Movers|
HIGHER: Ashland (ASH), up 4% after announcing that its board has approved proceeding with a plan to separate Ashland into two independent, publicly traded companies: the new Ashland, a provider of specialty chemical solutions, and Valvoline, which will focus on building the world's leading engine and automotive maintenance business... Solera Holdings (SLH), up 3% after Bloomberg reported that IHS (IHS) is considering besting Vista Equity Partners' $55.85 per share offer for Solera. Shares of IHS are up xxx% following the report... Weatherford (WFT), up 11% after stating that it has decided not to pursue its previously announced concurrent public offerings of ordinary shares of the company and mandatorily exchangeable subordinated notes. DOWN AFTER EARNINGS: Carnival (CCL), down 3.7%. ALSO LOWER: Groupon (GRPN), down 0.7% after announcing plans to cut 1,100 jobs relating primarily to the company's international operations... New Mountain Finance (NMFC), down 4% after its 5M share spot secondary priced at $14.14 per share... Memorial Resource Development (MRD), down 4% after announcing it acquired additional acreage in North Louisiana and pricing its 12M share spot secondary at $17.60 per share.
|09:02 EDT||GRPN||Groupon volatility flat into announcing restructuring, plans to cut 1,100 jobs|
Groupon September weekly call option implied volatility is at 51, October is at 48; compared to its 52-week range of 33 to 83, suggesting non-directional price movement into announcing a restructuring, plans to cut 1,100 jobs, sees pretax charges up to $35M.
|08:54 EDT||GRPN||Groupon to cut 1,100 jobs, sees pretax charges up to $35M|
In a regulatory filing, Groupon disclosed that its board of directors approved restructuring actions relating primarily to the company's international operations. These actions are expected to involve an overall reduction of approximately 1,100 positions globally and be substantially complete by September 2016. In connection with these actions, the company expects to record total pre-tax charges of up to $35M, including approximately $22M-$24M in the third quarter of 2015. Substantially all of the pre-tax charges are expected to be paid in cash and will relate to employee severance and compensation benefits, with an immaterial amount of the charges relating to asset impairments and other exit costs. The company intends to exclude the restructuring charges from its non-GAAP financial metrics, including Adjusted EBITDA and non-GAAP EPS. In addition, the company expects that any cost savings from the restructuring actions will be immaterial in 2015. Cost savings in subsequent years are expected to be primarily reinvested in the business.
|08:23 EDT||ABBV||Analysts say buy select biotech stocks ahead of Clinton drug plan|
Ahead of Presidential candidate Hillary Clinton laying out her plan to tackle "price gouging" in the specialty drug market at an event in Iowa later today, analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space. DEBATE: Biotech stocks broadly declined yesterday, with the NASDAQ Biotechnology index (IBB) sliding roughly 4.4%, after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on a 62-year-old drug that fights complication of AIDS and cancer. Furor around the sudden price hike for Turing's Daraprim reignited a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. The news also follows Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Pfizer's (PFE) Hospira, in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. Presidential candidate Hillary Clinton sent the debate to center stage yesterday by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan today to tackle "price gouging" in the specialty drug market. Clinton's proposal, which she'll outline in a speech in Iowa later today, would force pharmaceutical companies to reinvest their profits into research, allow for more generic and imported drugs and allow Medicare to negotiate lower drug costs and cap out-of-pocket expenses, according to details of the plan shared with USA Today. Zeke Emanuel, chair of medical ethics and health policy at the University of Pennsylvania, appeared on Nightly Business Report to discuss the problem of high drug prices and his suggested solutions. During his interview, Emanuel contended that giving Medicare the ability to negotiate drug prices may drive up prices for everyone else. DEFENSES: The Jefferies Biotechnology research team, led by Brian Abrahams, Eun Yang and Biren Amin, say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). Meanwhile, Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals (VRTX) following yesterday's selloff. Tenthoff believes that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. DOWNGRADE: Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, said Yang, who views the stock as more risky than in the past. PRICE ACTION: Horizon closed yesterday down $2.93, or 9.2%, at $28.99, while Vertex dropped $5.97, or 4.8%, to $118.19. A number of the biggest stocks in biotechnology were also weak yesterday, with Gilead sliding about 2.5%, Amgen (AMGN) dropping 2.3%, Celgene declining 2.8% and Biogen (BIIB) falling more than 5.5%.
|07:03 EDT||NURO||NeuroMetrix says Quell featured on 'Good Morning America'|
Subscribe for More Information
|06:19 EDT||ABBV||Clinton to roll out plan to rein in prescription drug costs, USA Today reports|
Subscribe for More Information
|September 21, 2015|
|16:53 EDT||ABBV||On The Fly: Top stock stories for Monday|
Stocks on Wall Street began the session in positive territory and remained there for most of the morning. The Nasdaq was the first index to show signs of weakness after Hillary Clinton pledged to address the high cost of specialty drugs, sinking multiple biotech stocks. The averages later recovered from their afternoon lows, with both the Dow and S&P posting gains and the Nasdaq narrowly finishing in the green after Monday's drug pricing debate. ECONOMIC EVENTS: In the U.S., existing home sales fell 4.8% to a 5.31M rate in August, versus expectations for them to be down 1.6% to a rate of 5.5M. Over the weekend, three Federal Reserve officials, namely San Francisco Fed President John Williams, St. Louis Fed President James Bullard and Richmond Fed President Jeffrey Lacker, all argued that an interest-rate increase is still warranted this year. COMPANY NEWS: Biotech stocks declined after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on its treatment for toxoplasmosis, reigniting a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. Presidential candidate Hillary Clinton sent the debate to center stage by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan tomorrow to tackle "price gouging" in the specialty drug market. The NASDAQ Biotechnology index fell roughly 4.4% following the attention paid to Turing's drug and Clinton's response... Shares of Volkswagen (VLKAY) trading in New York dropped 17.1% to $30.10 after the EPA and California Air Resources Board detected manipulations that violate U.S. environmental standards while testing certain Volkswagen diesel cars. The EPA said Volkswagen may face civil penalties of $37,500 for each vehicle not in compliance with federal clean air rules, which could total as much as $18B, according to Reuters... Apple (AAPL), which has previously been reported to be working on an electric car via its "Project Titan," is speeding up those efforts and setting 2019 as a target to ship its first vehicle, according to The Wall Street Journal. Shares of Tesla Motors (TSLA) were volatile following the Journal's report, but closed the day up 1.37% at $264.20. MAJOR MOVERS: Among the notable gainers was Atmel (ATML), which surged 12.65%, to $8.19 after agreeing to be acquired by German chipmaker Dialog Semiconductor in a deal valued at roughly $4.6B. Also higher was Starwood Waypoint (SWAY), which gained $2.89, or 12.70%, to $25.64 after announcing a stock-for-stock merger agreement with Colony American Homes. Additionally, Pandora (P) rose 8.17% to $21.31 after receiving an interim opinion from the Register of Copyrights regarding the company's agreements with Merlin and Naxos. Among the noteworthy losers was GoPro (GPRO), which fell $2.88, or 8.19%, to $32.27 after Barron's contended that the company's stock could plunge another 30% to $25 as Apple, Sony (SNE), and others pressure the company's "one-hit wonder" products. Also lower was Mallinckrodt (MNK), which lost $8.23, or 10.02%, to $73.87 after ANI Pharma (ANIP) announced plans to acquire two new drug applications from Merck (MRK) that could compete with Acthar, Mallinckrodt's largest product. Separately, D.R. Horton (DHI) dipped 2.91% after the August U.S. existing home sales report showed a 4.8% drop for the month. Note also that Lennar (LEN) slipped 0.27% after its quarterly earnings report beat analyst estimates. INDEXES: The Dow rose 125.61, or 0.77%, to 16,510.19, the Nasdaq added 1.73, or 0.04%, to 4,828.96, and the S&P 500 gained 8.94, or 0.46%, to 1,966.97.
|14:04 EDT||ABBV||Clinton vow to end drug price gouging sinks biotechs|
Biotech stocks have declined across the board in afternoon trading following a tweet by Presidential candidate Hillary Clinton criticizing the "outrageous" prices of specialty drugs. TURING STEPS UP PRICING: Clinton's tweet directly referenced Turing Pharmaceuticals' Daraprim treatment for toxoplasmosis, which recently had its price hiked from just $13.50 per pill to $750 after the privately-held company acquired the drug from Impax Laboratories (IPXL). Importantly, Daraprim was first approved by the FDA in 1953 and its patents have long since expired. No generic versions of the drug currently exist, perhaps in part due to Turing executive chairman Martin Shkreli's strategy of tightly controlling distribution, according to a New York Post article on the issue. In a Bloomberg TV interview this morning, Shkreli claimed that the drug remains underpriced compared to what he called its peers in the rare disease space. However, note that a World Health Organization analysis from 2013 reported that over 190,000 cases of toxoplasmosis occur globally every year and Daraprim continues to be listed on the organization's list of essential medicines for a basic health-care system. INDUSTRY CRITICISM: Turing's Daraprim pricing prompted a response from the Infectious Diseases Society of America and the HIV Medicine Association, which criticized the "unjustifiable" new cost of the drug and urged a "rational" pricing strategy. The news surrounding Daraprim also comes on the heels of Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Hospira (HSP), in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. REPUBLICAN CONGRESS: In a research note released this afternoon, RBC Capital analyst Michael Yee reminded investors that Republicans still control Congress, offering a sobering reminder that campaign trail promises often fall by the wayside once the candidate steps into office. Yee explained that, though drug pricing debates during next year's election will probably generate headline risk for the biotech space, the Republican-controlled Congress is unlikely to sign into law any material changes on the issue. BIOTECH STOCK ACTION: Hillary Clinton's promise to "lay out a plan" tomorrow to tackle "price gouging" in the specialty drug market sent numerous biotech stocks plunging. Aerie Pharmaceuticals (AERI) has crashed 12.6% at time of writing, while Retrophin (RTRX), Ultragenyx (RARE), and PTC Therapeutics (PTCT) are down 14.7%, 13.4%, and 11%, respectively. Biotech giants AbbVie (ABBV), Gilead (GILD), Bristol-Myers Squibb (BMY) and Biogen (BIIB) have also slipped in intraday trading, while the NASDAQ Biotechnology index is down roughly 4%.
|13:17 EDT||ABBV||RBC reminds biotech investors that Republicans still control Congress|
RBC Capital analyst Michael Yee notes that biotech indices are under pressure after Hillary Clinton tweeted about an upcoming plan to fight specialty drug pricing. The news follows a Wall Street Journal story about a private company dramatically increasing the price of their drug and another confirmed progressive multifocal leukoencephalopathy case for Biogen (BIIB), Yee tells investors in an intraday research note. Next year's election is likely to turn up the noise around drug pricing, creating headline risk for the biotech space, the analyst cautions. However, he reminds investors that Republicans control Congress, making it unlikely that "anything material" will get signed into law. Biotech names moving lower in today's trading include Biogen, AbbVie (ABBV), Gilead (GILD), Alkermes (ALKS), BioMarin (BMRN), Amicus (FOLD) and PTC Therapeutics (PTCT).
|10:00 EDT||SHPG||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: AerCap (AER) upgraded to Buy from Neutral at BofA/Merrill... Allstate (ALL) upgraded to Buy from Hold at Sandler O'Neill... Central Pacific (CPF) upgraded to Buy from Hold at Sandler ONeill... Cesca Therapeutics (KOOL) upgraded to Buy from Neutral at H.C. Wainwright... CyberArk (CYBR) upgraded to Buy from Hold at Deutsche Bank... DENTSPLY (XRAY) upgraded to Outperform from Market Perform at William Blair... DeVry (DV) upgraded to Outperform from Market Perform at Barrington... Douglas Emmett (DEI) upgraded to Buy from Neutral at Mizuho... Fly Leasing (FLY) upgraded to Neutral from Underperform at BofA/Merrill... Goldman Sachs (GS) upgraded to Outperform from Perform at Oppenheimer... Integra LifeSciences (IART) upgraded to Buy from Neutral at BofA/Merrill... Invesco (IVZ) upgraded to Overweight from Equal Weight at Morgan Stanley... LTC Properties (LTC) upgraded to Buy from Neutral at Mizuho... Molson Coors (TAP) upgraded to Buy from Hold at Societe Generale... Nokia (NOK) upgraded to Buy ahead of Samsung arbitration at Deutsche Bank... PayPal (PYPL) upgraded to Buy from Hold at Stifel... Shire (SHPG) upgraded to Overweight from Equal Weight at Barclays... Sirona Dental (SIRO) upgraded to Outperform from Market Perform at William Blair... Sonic (SONC) upgraded to Buy from Neutral at Longbow... Sun Life Financial (SLF) upgraded to Buy from Neutral at BofA/Merrill... Taylor Morrison (TMHC) upgraded to Buy from Hold at Deutsche Bank... Telecom Argentina (TEO) upgraded to Neutral from Underperform at BofA/Merrill... Vascular Biogenics (VBLT) upgraded to Outperform from Market Perform at JMP Securities... Yamana Gold (AUY) upgraded to Outperform from Neutral at Credit Suisse... lululemon (LULU) upgraded to Overweight from Equal Weight at Morgan Stanley.
|08:45 EDT||TXMD||On The Fly: Pre-market Movers|
HIGHER: Atmel (ATML), up 15% after agreeing to be acquired by Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share... uniQure (QURE), up 12% after announcing topline results of one-year follow-up data from a Phase I/II clinical trial in four Sanfilippo B syndrome patients... lululemon (LULU), up 3% after the stock was upgraded to Overweight at Morgan Stanley... Alcobra (ADHD), up 15% after announcing that the FDA has granted Fast Track designation to Metadoxine Extended Release for the treatment of Fragile X Syndrome... Denbury Resources (DNR), up 5% after announcing that its board has decided to suspend the company's current 6.25c per share quarterly cash dividend and reinstated the ability for the company to repurchase shares under its previously authorized share repurchase program, which was suspended in late 2014... TherapeuticsMD (TXMD), up 4% after Jefferies analyst Chris Howerton more than doubled his price target for shares to $15 from $7, citing a positive view Vagicap in vulvovaginal atrophy. LOWER: GoPro (GPRO), down 4% after Barron's contended in an article this weekend that the stock may slip another 30% despite its recent pullback... Weatherford (WFT), down 7.7% after announcing the launch of concurrent underwritten public offerings of ordinary shares and mandatory exchangeable subordinated notes for an expected combined amount of $1B... ImmunoGen (IMGN), down 4.7% after Morgan Stanley downgraded the stock to Underweight, stating that consensus estimates for its key asset, IMGN 853, remain too optimistic on the potential success of an upcoming Phase II study.
|07:39 EDT||TXMD||TherapeuticsMD price target raised to $15 from $7 at Jefferies|
Subscribe for More Information
|06:56 EDT||SHPG||Shire upgraded to Overweight from Equal Weight at Barclays|
Subscribe for More Information
|05:09 EDT||SHPG||Shire receives European approval for INTUNIV as ADHD treatment|
Subscribe for More Information